## FORM 4

longer subject to

may continue. See

Instruction 1(b).
(Print or Type Responses)

Section 16. Form 4 or Form 5 obligations

# M 4 UNITED STATES SE

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVA	۱L
OMB Number: 3	235-0287
Estimated average burd	en
hours per response	0.5

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *- Lasaga Joseph			2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]					5. F	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner						
(Last) (First) (Middle) RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD.			` [	3. Date of Earliest Transaction (Month/Day/Year) 02/02/2017					X	Officer (giv	ve title below) VP Bus. De	Othev.& Allianc	er (specify below e Mgmt.	v)	
(Street) SOUTH SAN FRANCISCO, CA 94080			4. If Amendment, Date Original Filed(Month/Day/Year)						_X_	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person					
(City) (State) (Zip)				Table I - Non-Derivative Securities Acqu						s Acquired	lired, Disposed of, or Beneficially Owned				
(Instr. 3) Date		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, any (Month/Day/Ye		te, if C		(A	(A) or Disposed of (D) (Instr. 3, 4 and 5)		5. Amount of Securities Beneficia Owned Following Reported Transaction(s)		i	Ownership Form:	Beneficial	
				(Month/	/Day/1	y ear)	Code	e V A	mount (A) or (D)	Price	(Instr. 3 and 4)			Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)
								in this f	orm are not re	eauired to	respond	unless the	form		
			Table II -					displays	orm are not re s a currently v sed of, or Bene avertible secur	valid OMB	control r		form		
1. Title of Derivative Security (Instr. 3)	Conversion	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if	4. Transact	tion 5 S A O O (I	<b>ls, warr</b> . Numb	er ative es d (A) sed	displays  ired, Dispo options, cor  6. Date Exe	sed of, or Beneavertible securicisable and	valid OMB	ned d Amount	umber.	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction	Ownersh Form of Derivativ Security Direct (I or Indire	(Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transact	tion 5 S A O O (I	Is, warr Numb of Deriva Securitie Acquired or Dispo of (D) Instr. 3,	er ative es d (A) sed 4,	displays  nired, Dispo options, cor  6. Date Exe Expiration I	sed of, or Beneavertible securicisable and Date //Year)	ficially Owities)  7. Title and of Underly Securities	ned d Amount	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	Ownersh Form of Derivativ Security Direct (I or Indire	of Indirect Beneficial Ownersh (Instr. 4)

#### **Reporting Owners**

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Lasaga Joseph RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080			VP Bus. Dev.& Alliance Mgmt.			

#### **Signatures**

/s/ Dolly A. Vance (Atorney-in-Fact)	02/06/2017
**Signature of Reporting Person	Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares vest monthly over four (4) years from January  $1,\,2017.$

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.